Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges

Shinya Yamanaka

doi:10.1016/j.stem.2020.09.014

Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges

Cell Stem Cell. 2020 Oct 1;27(4):523-531. doi: 10.1016/j.stem.2020.09.014.

Author

Shinya Yamanaka¹

Affiliation

¹ Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan; Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA. Electronic address: yamanaka@cira.kyoto-u.ac.jp.

PMID: 33007237
DOI: 10.1016/j.stem.2020.09.014

Abstract

Human pluripotent stem cells such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) provide unprecedented opportunities for cell therapies against intractable diseases and injuries. Both ESCs and iPSCs are already being used in clinical trials. However, we continue to encounter practical issues that limit their use, including their inherent properties of tumorigenicity, immunogenicity, and heterogeneity. Here, I review two decades of research aimed at overcoming these three difficulties.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Cell- and Tissue-Based Therapy
Embryonic Stem Cells
Humans
Induced Pluripotent Stem Cells*
Pluripotent Stem Cells*
Stem Cell Transplantation